Kineret (anakinra), a new biotech drug for rheumatoid arthritis
Amgen is now launching Kineret (anakinra), a new biotech drug for rheumatoid arthritis.
It's the first interleukin-1 (IL-1) receptor antagonist.
Blocking this protein reduces joint pain and inflammation...and might slow the progression of the disease.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote